Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study
Authors' conclusion
Beta-cell function was associated with achieving TIR and TAR targets. Stimulating insulin secretion or exogenous insulin treatment could not overcome the disadvantage of lower beta-cell function on glycaemic control.
Study context
- Population
- Inpatients with T2D undergoing antidiabetic treatment
- Participants
- 180 inpatients
- Exposure
- Lower vs higher beta-cell function
- Outcome
- Achieving TIR (>70%) and TAR (<25%) targets assessed by CGM
- Follow-up
- Following antidiabetic treatment
Main finding
As reported in the abstract
Lower ISSI2 and not achieving TIR/TAR targets (logistic regression, adjusted)
Lower ISSI2, fewer achieving time in range (TIR) target: OR
3.10 (1.19-8.06) (95% CI)
Lower ISSI2, fewer achieving time above range (TAR) target: OR
3.40 (1.35-8.55) (95% CI)
Observational data: associations, not effects.
Further findings
Subgroup treated with insulin secretagogues
- TIR: OR (95% CI), P
- 2.91 (0.90-9.36), P = .07
- TAR: OR
- 3.14 (1.01-9.80) (95% CI)
Subgroup on adequate insulin therapy
- TIR: OR (95% CI), P
- 2.84 (0.91-8.81), P = .07
- TAR: OR
- 3.24 (1.08-9.67) (95% CI)
Diagnostic value (ROC) of ISSI2 for achieving targets
- TIR target
- 0.73 (0.66-0.80) (95% CI)
- TAR target
- 0.71 (0.63-0.79) (95% CI)
Original publication
Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study. Diabetes Obes Metab. Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →